Clinical Trial Update: Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Radium-223 in asymptomatic metastatic castration-resistant prostate cancer patients on Abiraterone or Enzalutamide, with AR-V7 status a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: MedSIR | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-12-11